Ocular Therapeutix, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Ocular Therapeutix's 2025 annual report reveals widening net losses and declining DEXTENZA revenue, despite significant advancements in its AXPAXLI clinical programs and a substantial capital raise.
NASDAQ
Ocular Therapeutix provides an update on its key programs, including AXPAXLI's Phase 3 trials and DEXTENZA's pediatric study submission, in its annual 10-K filing.
NASDAQ
Ocular Therapeutix appoints new executives, provides updates on clinical trials, and reports financial results.